{"version":"1.0","provider_name":"IFPMA","provider_url":"https:\/\/www.ifpma.org","title":"Research-based biopharmaceutical industry on the TRIPS waiver discussions at WTO Ministerial Conference (MC12) | IFPMA","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"Ec1bQD3FOG\"><a href=\"https:\/\/www.ifpma.org\/news\/research-based-biopharmaceutical-industry-on-the-trips-waiver-discussions-at-wto-ministerial-conference-mc12\/\">Research-based biopharmaceutical industry on the TRIPS waiver discussions at WTO Ministerial Conference (MC12)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.ifpma.org\/news\/research-based-biopharmaceutical-industry-on-the-trips-waiver-discussions-at-wto-ministerial-conference-mc12\/embed\/#?secret=Ec1bQD3FOG\" width=\"600\" height=\"338\" title=\"&#8220;Research-based biopharmaceutical industry on the TRIPS waiver discussions at WTO Ministerial Conference (MC12)&#8221; &#8212; IFPMA\" data-secret=\"Ec1bQD3FOG\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"The associations representing the global research-based biopharmaceutical industry reaffirm that weakening the intellectual property (IP) framework as proposed in the \u201cQuad compromise\u201d is unnecessary and harmful to innovation. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk. It will undermine innovation and industry\u2019s ability to...","thumbnail_url":"https:\/\/www.ifpma.org\/wp-content\/uploads\/2023\/04\/ifpma-logo-social-preview.png","thumbnail_width":801,"thumbnail_height":801}